Welcome to our dedicated page for Nextcure SEC filings (Ticker: NXTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NextCure, Inc. filings document a clinical-stage oncology issuer's financial reporting, governance, capital structure, and material-event disclosures. Recent Form 8-K reports furnish quarterly and annual results, business update exhibits, Regulation FD materials on ADC programs, officer transition disclosure, a completed private placement of common stock and pre-funded warrants, and an effected reverse stock split.
The company's proxy materials cover annual meeting matters including director elections, auditor ratification, say-on-pay, board governance, and executive compensation for a Delaware corporation with Nasdaq-listed common stock.
Squadron Master Fund LP and related parties report a significant stake in NextCure, Inc. common stock. They beneficially own 271,127 shares, including 236,966 shares of common stock and 34,161 shares issuable upon exercise of warrants. This position represents approximately 9.99% of NextCure’s common stock, based on 2,679,822 shares outstanding as of October 31, 2025 plus the warrant shares. The securities are held in the ordinary course of business and are not reported as being acquired to change or influence control of NextCure.
Pfizer Inc. and its affiliate Pfizer Ventures (US) LLC have updated their ownership disclosure for NextCure, Inc. common stock in an amended Schedule 13G. Pfizer reports beneficial ownership of 157,646 shares, representing 3.0% of the common stock, with 26,537 shares under sole voting and dispositive power and 131,109 shares under shared voting and dispositive power. Pfizer Ventures (US) LLC reports beneficial ownership of 131,109 shares, or 2.5% of the class, all with shared voting and dispositive power. These percentages are based on 5,203,290 shares outstanding as reported in NextCure’s final prospectus, which includes 1,815,049 shares issuable upon exercise of pre-funded warrants. The reporting persons certify that the securities are held without the purpose or effect of changing or influencing control of NextCure.
SilverArc Capital Management, LLC and its sole member Devesh Gandhi report beneficial ownership of 176,057 shares of NextCure, Inc. Class A common stock, representing 5.02% of the class as of 12/31/2025. All voting and dispositive power over these shares is shared, with no sole authority reported.
SilverArc is an SEC-registered investment adviser, and the shares are held for various advisory clients, who have the right to receive dividends and sale proceeds. Within this total, SilverArc Capital Alpha Fund I, L.P. is attributed 6,162 shares (about 0.18%), and SilverArc Capital Alpha Fund II, L.P. is attributed 169,895 shares (about 4.85%). The filing states the position is held in the ordinary course of business and not for the purpose of influencing control of NextCure.
NextCure, Inc. reported that its Sr VP and General Counsel, Kevin G. Shaw, received an employee stock option grant. On January 30, 2026, he was awarded an option to buy 8,270 shares of common stock at an exercise price of $10.85 per share.
According to the vesting schedule, one fourth of the option vests on January 30, 2027, and the remaining three fourths vest in 36 monthly installments beginning February 28, 2027. Following this grant, he beneficially holds 8,270 stock options directly.
NextCure, Inc. reported that its Chief Medical Officer, Udayan Guha, received an employee stock option grant on January 30, 2026. The option covers 14,670 shares of common stock at an exercise price of $10.85 per share and is held directly.
One quarter of the option vests on January 30, 2027, with the remaining three quarters vesting in 36 monthly installments starting February 28, 2027. The option expires on January 29, 2036 if not exercised.
NextCure, Inc. reported that Senior Vice President of Development and Manufacturing Sourav K. Kundu received an employee stock option grant. On January 30, 2026, he was awarded options to buy 8,270 shares of common stock at an exercise price of $10.85 per share.
One fourth of the option vests on January 30, 2027, with the remaining portion vesting in 36 monthly installments beginning February 28, 2027. Following this grant, Kundu beneficially owns 8,270 stock options, all held directly.
NextCure, Inc. reported that its Chief Operating Officer, Timothy Mayer, received an award of employee stock options. The grant covers 14,670 options with an exercise price of $10.85 per share and was dated January 30, 2026.
One fourth of the option grant vests on January 30, 2027, with the remaining options vesting in 36 monthly installments beginning February 28, 2027. Mayer holds all 14,670 derivative securities directly following this award.
NextCure, Inc. reported that President and CEO Michael Richman received a grant of 38,190 employee stock options on January 30, 2026. These options have an exercise price of $10.85 per share and expire on January 29, 2036.
According to the vesting schedule, one fourth of the option grant vests on January 30, 2027, with the remaining options vesting in 36 equal monthly installments beginning on February 28, 2027. Following this grant, Richman beneficially owns 38,190 derivative securities directly.
NextCure, Inc. insider filing shows a new stock option grant to its Chief Financial Officer, Steven P. Cobourn. On January 30, 2026, he received an employee stock option to buy 14,670 shares of NextCure common stock at an exercise price of $10.85 per share.
According to the vesting schedule, one fourth of the option vests on January 30, 2027, with the remaining three fourths vesting in 36 equal monthly installments starting February 28, 2027. This type of award is a standard form of equity compensation that links executive pay to the company’s future stock performance.
Affinity Asset Advisors, LLC and Michael Cho report a 9.99% beneficial stake in NextCure, Inc. common stock. They disclose beneficial ownership of 348,607 shares of Common Stock, based on 3,489,563 shares outstanding as of October 31, 2025.
The position includes 101,313 shares issuable upon exercise of warrants, which are subject to a 9.99% beneficial ownership limitation that caps how many shares can be acquired through exercise. The securities are held through Affinity Healthcare Fund, LP, for which Affinity Asset Advisors serves as investment manager and over which it exercises voting and investment power.
The filers state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of NextCure. Both reporting persons certify the accuracy and completeness of the ownership information as of late January 2026.